CYBN
Cybin, Inc. · AMEX
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website cybin.com
- Employees(FY) 50
- ISIN CA23256X1006
Performance
+6.8%
1W
-14.07%
1M
+12.59%
3M
-27.54%
6M
-8.83%
YTD
+21.36%
1Y
Profile
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
Technical Analysis of CYBN 2024-05-03
Overview:
In analyzing the technical indicators for CYBN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Indicators:
- Moving Averages (MA): The 5-day MA has been consistently below the closing price, i...
Recent News & Updates
- 2024-05-05 20:32
- 2024-04-24 19:30
- 2024-04-17 19:30
- 2024-04-15 19:30
- 2024-04-09 19:30
- 2024-03-18 23:53
- 2024-03-17 19:30
- 2024-03-14 19:30
- 2024-03-13 19:30
- 2024-03-12 19:00
- 2024-03-12 18:00
- 2024-03-12 10:37
- 2024-02-26 18:30
- 2024-02-13 18:45
- 2024-02-06 18:30
- 2024-01-28 04:02
Weekly Roundup on the Cannabis Sector & Psychedelic Sector(Yahoo Finance)
- 2024-01-23 20:00
- 2024-01-22 18:30
- 2024-01-07 18:34
- 2024-01-03 18:32
- 2023-12-05 18:30
- 2023-12-04 18:30
- 2023-11-29 18:30
- 2023-11-19 18:30
- 2023-11-15 18:30
- 2023-11-14 18:30
- 2023-11-14 06:16
- 2023-11-14 00:00
- 2023-11-09 19:13
- 2023-11-09 19:05
Page 1 of 4
previousnext